drugset / Trial / NCT07081256

To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

NCT07081256

Phase 3 Completed 665 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Compared With Fosaprepitant dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of QLM2010 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

Timeline

Start
2025-01-03
Primary completion
2025-08-25
Completion
2025-10-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Palonosetron Other / unclassified
Subject QLM2010 Unknown
Comparator fosaprepitant dimeglumine Unknown
Background Dexamethasone Small molecule